Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery
Sponsor : n-Lorem Foundation
Deal Size : Undisclosed
Deal Type : Collaboration
n-Lorem Foundation Collaborates to Support Children With Extremely Rare Diseases
Details : The collaboration aims to accelerate the development of optimized experimental antisense oligonucleotide (ASO) medicines for pediatric patients with extremely rare genetic neurological disorders.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
April 10, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery
Sponsor : n-Lorem Foundation
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Renaissance Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Renaissance gains exclusive development, manufacturing and commercialisation rights for Hu14.18K322A, an anti GD2 humanised mAb in development by St. Jude for the treatment of newly diagnosed high-risk neuroblastoma.
Product Name : Hu14.18K322A
Product Type : Antibody
Upfront Cash : Undisclosed
January 08, 2023
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Renaissance Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Streptococcus Pneumoniae Vaccine
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Undisclosed
Sponsor : Blue Water Vaccines
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Blue Water Licenses Patent Rights for bacterial Vaccine Development
Details : Blue Water Vaccines has entered into an exclusive worldwide license agreement for the development of a Streptococcus Pneumoniae vaccine with St. Jude Children's Research Hospital.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
October 02, 2020
Lead Product(s) : Streptococcus Pneumoniae Vaccine
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Undisclosed
Sponsor : Blue Water Vaccines
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Venetoclax,Navitoclax
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the Phase 1 study, Venetoclax with Navitoclax and chemotherapy was well tolerated and had promising efficacy in heavily pretreated pediatric patients with ALL and LL.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 12, 2020
Lead Product(s) : Venetoclax,Navitoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable